# NCT04292119 (NCT04292119)

> Lorlatinib Combinations in Lung Cancer

No report yet. It can be ordered.

- Indication: anaplastic lymphoma kinase-rearranged lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04292119
- Phase: PHASE1, PHASE2
- Status: UNKNOWN
- Sponsor: Massachusetts General Hospital
- Conditions: Lung Cancer; Anaplastic Lymphoma Kinase Gene Translocation; ROS1 Rearrangement; Relapsed Cancer; MET Amplification; Resistant Cancer; NSCLC
- Interventions: Lorlatinib; Crizotinib; Binimetinib; TNO155
- Enrollment: 96
- Primary outcome: Maximum tolerated dose as assessed by CTCAE v5.0. Phase I.
- Primary outcome: The objective response rate, including partial and complete responses, as evaluated by RECIST v1.1. Phase II

## Indexed commentary on NCT04292119 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct04292119